Michael J Erdman1, Heidi Riha2, Lauren Bode3, Jason J Chang4, G Morgan Jones5. 1. Pharmacy Department, University of Florida Health, Jacksonville, FL, USA. 2. Pharmacy Department, Methodist University Hospital, Memphis, TN, USA. 3. Pharmacy Department, University of North Carolina Hospitals and Clinics, Chapel Hill, NC, USA. 4. Department of Neurology, University of Tennessee Health Sciences Center, Memphis, TN, USA. 5. Pharmacy Department, Methodist University Hospital, Memphis, TN, USA; Pharmacy Department, University of Tennessee Health Sciences Center, Memphis, TN, USA.
Abstract
BACKGROUND AND PURPOSE: Continuous intravenous 3% hypertonic saline (HTS) infusions are commonly used for the management of cerebral edema following severe neurologic injuries. Despite widespread use, data regarding the incidence and predictors of nephrotoxicity are lacking. The purpose of this study was to describe the incidence and identify predictors of acute kidney injury (AKI) in neurocritical care patients administered continuous infusion HTS. METHODS: This was an institutional review board-approved, multicenter, retrospective cohort study of patients receiving HTS infusions at 2 academic medical centers. A univariate analysis and multivariable logistic regression were used to identify predictors of AKI. Data regarding AKI were evaluated during treatment with HTS and up to 24 hours after discontinuation. RESULTS: A total of 329 patients were included in our analysis, with 54 (16%) developing AKI. Those who developed AKI experienced significantly longer stays in the intensive care unit (14.8 vs 11.5 days; P = .006) and higher mortality (48.1% vs 21.9%; P < .001). We identified past medical history of chronic kidney disease (odds ratio [OR]: 9.7, 95% confidence interval [CI]: 1.9-50.6; P = .007), serum sodium greater than 155 mmol/L (OR: 4.1, 95% CI: 2.1-8.0; P < .001), concomitant administration of piperacillin/tazobactam (OR: 3.9, 95% CI: 1.7-9.3; P = .002), male gender (OR: 3.2, 95% CI: 1.5-6.6; P = .002), and African American race (OR: 2.6, 95% CI: 1.3-5.2; P = .007) as independent predictors of AKI. CONCLUSION: Acute kidney injury is relatively common in patients receiving continuous HTS and may significantly impact clinical outcomes.
BACKGROUND AND PURPOSE: Continuous intravenous 3% hypertonicsaline (HTS) infusions are commonly used for the management of cerebral edema following severe neurologic injuries. Despite widespread use, data regarding the incidence and predictors of nephrotoxicity are lacking. The purpose of this study was to describe the incidence and identify predictors of acute kidney injury (AKI) in neurocritical carepatients administered continuous infusion HTS. METHODS: This was an institutional review board-approved, multicenter, retrospective cohort study of patients receiving HTS infusions at 2 academic medical centers. A univariate analysis and multivariable logistic regression were used to identify predictors of AKI. Data regarding AKI were evaluated during treatment with HTS and up to 24 hours after discontinuation. RESULTS: A total of 329 patients were included in our analysis, with 54 (16%) developing AKI. Those who developed AKI experienced significantly longer stays in the intensive care unit (14.8 vs 11.5 days; P = .006) and higher mortality (48.1% vs 21.9%; P < .001). We identified past medical history of chronic kidney disease (odds ratio [OR]: 9.7, 95% confidence interval [CI]: 1.9-50.6; P = .007), serum sodium greater than 155 mmol/L (OR: 4.1, 95% CI: 2.1-8.0; P < .001), concomitant administration of piperacillin/tazobactam (OR: 3.9, 95% CI: 1.7-9.3; P = .002), male gender (OR: 3.2, 95% CI: 1.5-6.6; P = .002), and African American race (OR: 2.6, 95% CI: 1.3-5.2; P = .007) as independent predictors of AKI. CONCLUSION:Acute kidney injury is relatively common in patients receiving continuous HTS and may significantly impact clinical outcomes.
Authors: Diane M Gomes; Carmen Smotherman; Amy Birch; Lori Dupree; Bethany J Della Vecchia; Dale F Kraemer; Christopher A Jankowski Journal: Pharmacotherapy Date: 2014-04-18 Impact factor: 4.705
Authors: Carsten M Schmalfuss; Pamela K Woodard; Michael J Gitter; Manoj P Jadhav; Raye L Bellinger; Steven C Rose; Anthony A Bavry Journal: Int J Cardiol Date: 2014-08-19 Impact factor: 4.164
Authors: Avinash B Kumar; Yaping Shi; Matthew S Shotwell; Justin Richards; Jesse M Ehrenfeld Journal: Neurocrit Care Date: 2015-04 Impact factor: 3.210
Authors: David D Gonda; Hal S Meltzer; John R Crawford; Mary L Hilfiker; David K Shellington; Bradley M Peterson; Michael L Levy Journal: Pediatr Crit Care Med Date: 2013-07 Impact factor: 3.624
Authors: P Piccinni; D N Cruz; S Gramaticopolo; F Garzotto; M Dal Santo; G Aneloni; M Rocco; E Alessandri; F Giunta; V Michetti; M Iannuzzi; C Belluomo Anello; N Brienza; M Carlini; P Pelaia; V Gabbanelli; C Ronco Journal: Minerva Anestesiol Date: 2011-05-11 Impact factor: 3.051
Authors: R Dittrich; S Akdeniz; S P Kloska; T Fischer; M A Ritter; P Seidensticker; W Heindel; E B Ringelstein; D G Nabavi Journal: J Neurol Date: 2007-11-09 Impact factor: 4.849
Authors: Cornelia B Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig; Jürgen B Bulitta; Ulrike Holzgrabe; Fritz Sörgel Journal: Br J Clin Pharmacol Date: 2008-11 Impact factor: 4.335
Authors: J J Hopyan; D J Gladstone; G Mallia; J Schiff; A J Fox; S P Symons; B H Buck; S E Black; R I Aviv Journal: AJNR Am J Neuroradiol Date: 2008-08-21 Impact factor: 3.825
Authors: Jens-Ulrik Stæhr Jensen; Lars Hein; Bettina Lundgren; Morten Heiberg Bestle; Thomas Mohr; Mads Holmen Andersen; Klaus Julius Thornberg; Jesper Løken; Morten Steensen; Zoë Fox; Hamid Tousi; Peter Søe-Jensen; Anne Øberg Lauritsen; Ditte Gry Strange; Nanna Reiter; Katrin Thormar; Paul Christian Fjeldborg; Kim Michael Larsen; Niels-Erik Drenck; Maria Egede Johansen; Lene Ryom Nielsen; Christian Ostergaard; Jesper Kjær; Jesper Grarup; Jens D Lundgren Journal: BMJ Open Date: 2012-03-11 Impact factor: 2.692
Authors: Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin Journal: Crit Care Date: 2007 Impact factor: 9.097
Authors: Hannah Hewgley; Stephen C Turner; Joseph E Vandigo; Jacob Marler; Heather Snyder; Jason J Chang; G Morgan Jones Journal: Neurocrit Care Date: 2018-06 Impact factor: 3.210
Authors: Aaron M Cook; G Morgan Jones; Gregory W J Hawryluk; Patrick Mailloux; Diane McLaughlin; Alexander Papangelou; Sophie Samuel; Sheri Tokumaru; Chitra Venkatasubramanian; Christopher Zacko; Lara L Zimmermann; Karen Hirsch; Lori Shutter Journal: Neurocrit Care Date: 2020-06 Impact factor: 3.210